^
Association details:
| Biomarker: | NRAS G13D + BRAF V600E |
|---|---|
| Cancer: | Thyroid Gland Carcinoma |
| Drug Class: | BRAF inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors
Published date:
09/08/2020
Excerpt:
Patients 1 and 3 acquired a KRASG12V mutation in the progressive tumor, patient 2 acquired a NRASQ61K mutation in a progressive lymph node, and patient 4 acquired NRASG13D mutation on liquid biopsy performed at the time of radiographic disease progression....the emergence of RAS mutations appears to act as a mechanism of resistance to BRAF inhibitors in thyroid cancers.
DOI:
10.1089/thy.2019.0514
